Goserelin

Overview

Goserelin, marketed as Zoladex, is a synthetic decapeptide analogue of gonadotropin-releasing hormone (GnRH, also called LHRH). It is formulated as a biodegradable depot implant injected under the skin, where it slowly dissolves and releases the drug over weeks. This sustained delivery means patients receive treatment at scheduled intervals rather than daily.

Goserelin is used in the management of hormone-sensitive prostate cancer in men, breast cancer and certain benign gynecological conditions in women, including endometriosis and uterine fibroids, and it is sometimes used before endometrial procedures to thin the uterine lining. Its central purpose is to lower sex hormone levels by acting on the pituitary gland.

As a GnRH agonist, goserelin initially stimulates hormone release before producing suppression. This biphasic effect, often called the flare, is an important clinical consideration, particularly in advanced prostate cancer.

How it works

Normally, the hypothalamus releases GnRH in pulses, prompting the pituitary to secrete luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn drive testosterone production in the testes and estrogen production in the ovaries.

Goserelin binds to pituitary GnRH receptors and, because it is delivered continuously rather than in pulses, it first triggers a surge of LH and FSH. This causes a temporary rise in testosterone or estrogen, the so-called flare. With ongoing exposure, the pituitary receptors become desensitized and downregulated, so LH and FSH output falls sharply.

The result is a profound, reversible reduction in sex hormone levels, reaching castrate-range testosterone in men or low estrogen in women. Because many prostate and breast cancers depend on these hormones for growth, lowering them can slow disease activity. Hormone levels typically recover after treatment stops.

Clinical evidence

Goserelin has been studied and used clinically for several decades and is a well-established option in oncology and gynecology. In prostate cancer, GnRH agonists like goserelin are a standard form of androgen deprivation therapy, used alone or alongside radiotherapy, surgery, or other systemic treatments.

In premenopausal breast cancer, goserelin has been evaluated for ovarian suppression, including its role in fertility-related research such as the POEMS/SWOG trial program, which examined ovarian protection during chemotherapy. In gynecology, it has been studied for symptom control in endometriosis and for reducing fibroid size before surgery.

Evidence consistently shows goserelin effectively suppresses sex hormones. Its place in therapy depends on the specific condition, disease stage, and individual factors, and treatment decisions are made by specialists weighing benefits against side effects.

Dosing & side effects

Goserelin is administered by a healthcare professional as a depot implant placed under the skin of the abdomen at regular intervals. The specific product strength and schedule are determined by the treating clinician based on the condition being managed. This page does not provide dosing instructions.

Because goserelin lowers sex hormones, side effects often resemble those of menopause or low testosterone. These can include hot flashes, sweating, reduced libido, sexual dysfunction, mood changes, and fatigue. Longer-term use is associated with reduced bone mineral density, and metabolic and cardiovascular considerations may arise during prolonged therapy.

In men with advanced prostate cancer, the initial testosterone flare can briefly worsen symptoms, so an anti-androgen is often given around the start of treatment. Local injection-site reactions are possible. Patients should discuss monitoring and risk management with their care team.

Legal status

Goserelin is an FDA-approved prescription medication and is similarly approved by regulators in many countries. It is dispensed only under medical supervision and administered by trained healthcare professionals.

It is not available over the counter and is not a substance intended for self-administration or non-medical use. Its approved indications, which include certain prostate cancers, breast cancers, and benign gynecological conditions, are defined by regulatory authorities and product labeling.

Because goserelin is a clinician-administered depot implant requiring careful patient selection and monitoring, access is tightly tied to specialist care. Patients should obtain it only through legitimate medical channels.

Frequently asked questions

References

Each source links to its original record — peer-reviewed studies, regulator pages, or reference texts, labelled by type. We summarize findings neutrally; a citation is a reference, not an endorsement, and not a claim that its authors reviewed this page.

1. Cockshott ID. Clinical pharmacokinetics of goserelin. Clin Pharmacokinet. 2000. Peer-reviewed study
2. Mitchell H. Goserelin ('Zoladex')--offering patients more choice in early breast cancer. Eur J Oncol Nurs. 2004. Peer-reviewed study
3. Cheer SM, Plosker GL, Simpson D, et al. Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women. Drugs. 2005. Peer-reviewed study
4. Klarskov P, Andersen AN, Trokmar M. [Goserelin]. Ugeskr Laeger. 1990. Peer-reviewed study
5. Brogden RN, Faulds D. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in prostate cancer. Drugs Aging. 1995. Peer-reviewed study
6. Perry CM, Brogden RN. Goserelin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in benign gynaecological disorders. Drugs. 1996. Peer-reviewed study